
MONDAY, Jan. 24, 2022 (healthDay News) — The U.S. Food and Drug Administration said Monday that it will curtail the use of two monoclonal antibody treatments that do not appear to work against the highly contagious Omicron variant. The combo treatments bamlanivimab/etesevimab and casirivimab/imdevimab, made by Eli Lilly and Regeneron, respectively, performed well against earlier… read on > read on >